Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mine's only worth $174 I need .483 just to be even. I'm either going to make money or lose it all, no since selling out now.
my investment in ADLS is now worth $8.70 lol!
http://www.scribd.com/doc/39735661/Getting-Rich-on-Uncle-Sucker
http://warisacrime.org/node/23067
I was hoping the grant in July would give them enough money to bribe the FDA which is what it takes to get a drug approved.
Vanda (2008) has a drug that received a non-approval because Eli Lilly had a similar drug coming out within the next 6 or 7 months. When Lilly admitted thier drug didn't work Vanda received thier approval in about a month. I sat on Vanda for over a year but made a killin when the approval came through.
The 2 articles are kinda long but worth the read.
exactly right. adls should be a multi-million dollar company, if not for the fda changing the rules mid-game. most frustrating.
another one bites the dust. another fda casualty here !
Flavin owns the building that ADLS pays rent to. cha-ching, nothing better than free real estate. plus he collects a nice fat paycheck and i believe he owns rights to cethro.
he has safeguarded his retirement through diversification, smart on his part, just not good for the company nor shareholders.
You are so right, those damn rich people all they want to do is make money. Oh wait isn't that why we are all here? Maybe he didn't sell out because he thought if they could hold on until they received the grant in July they would have enough money to bribe the FDA just like the big boys. If all he was after was money wouldn't he have sold out years ago instead of loosing money for the last two years trying to get an approval from one of the top 5 corrupt government agencies. The FDA ranks right up there with the DOJ, EPA, Fannie and Freddie.
I can see into the future, come to my kingdom to see what else i can do. ADLS has failed, its too darn bad too, because they have a drug with great capabilities, should have been approved back in 09.
Flavin should have sold out a long time ago, but perhaps he loves his +100k salary too much.
Advanced Life Sciences Suspends Operations
http://www.prnewswire.com/news-releases/advanced-life-sciences-suspends-operations-121350958.html
CHICAGO, May 5, 2011 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTCBB: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has suspended operations and terminated its staff due to its severe lack of liquidity.
"We presently do not have sufficient cash to fund our operations and have curtailed substantially all activities," stated the Company's Chairman and Chief Executive Officer, Dr. Michael T. Flavin. The Company's Board of Directors is considering all strategic alternatives in light of the Company's current financial circumstances, and the suspension of operations will limit the Company's need for working capital while it continues to explore possible solutions. The Company's ability to continue as a going concern will depend on the results of the Board's efforts, and a filing under the federal bankruptcy laws is a distinct possibility.
Thanks for the quick reply Andy
Regards
Ammobox
Although charts are said to "price everything in", it is important to keep an eye on fundamentals as well. If you look at the chart, you'll see the R/S seems to have already had a substantial effect on the stock.
Andy,
Does your stock chart take in account that ADLS just had a 1 for 30 reverse stock split? or would that matter?
I'm not a chart guru and had that question on my mind. So I thought I'd ask.
If anyone else knows the answer please post 8-)
Reverse Stock Split
The Company also announced today that a 1-for-30 reverse split of its common stock will take effect at 5:00 p.m. on Monday, March 28, 2011. The Company's common stock will be quoted on the OTC Bulletin Board on a split-adjusted basis beginning upon the opening of trading on March 29, 2011, under the symbol of ADLSD.OB. After 20 business days, the symbol will revert back to ADLS.OB.
As a result of the reverse stock split, every 30 shares of the Company's common stock issued and outstanding or reserved for issuance immediately prior to the effective time will be converted into one share of common stock. Fractional shares will not be issued and stockholders who otherwise would have been entitled to receive a fractional share as a result of the reverse stock split will receive an amount in cash the closing sales price of the Company's common stock as reported on the OTC Bulletin Board on March 28, 2011.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61298566
Thanks
Ammobox
ADLS Video Chart 5/4/11
http://www.videocharts.qualitystocks.net
Advanced Life Sciences Holdings Inc. is not a current client of QualityStocks
Up today 16%!!!!
Who turned out the lights. This used to be a favorite for some.
WealthyKing......Your one and only post to the adls board and it's on April 4 and it's a letter to the share holders dated April 11. It's April 12 now and I haven't received anything yet from the company. Has anyone else?
I have been out since July 09...waiting also to get back in...hopefully when the time is right...good luck...I still have faith....in the drug only...for now
From buy to hold, no choice...
Oh yes, I believe in the pipeline. And, I held through the reverse
split. But, lo and behold, nothing prepped longs to be diluted 80% plus in one fell swoop on top of the dilution. That's a horse of a different color.
To my senses, the Flavins were selling one day, the day we hit 600K
in volume last week. They have enough shares to do that 400 more times.
Needless to say, I took my 53% loss on a 5% position, a 2.5% overall whack to my total net worth.
What was our market cap usually? $5 million? That means good old ADLSD is headed for a nickle and below.
They need that grant this summer. No grant, I cannot tell any more how deep this crater is.
And, issuing that many shares was unnecessary. They need $1.6 M. per quarter to cover their burn rate. 10 M. new shares would have been fine, perhaps 15 M. to carry them through the end of July.
Instead, they whacked us heavy and hard.
I will be watching, but until I see a proper funding source in place, be it a grant or a government contract, I am not coming back again.
Lastly, it is my unfounded monkey suspicion that someone in this world, someone in Big Pharma, has called in a few favors to put a few hurdles in front of this company and cithro. It is just too silly how long it is taking to put this drug through the process.
The FDA is moving too slow, requiring unusual degrees of efficacy,
forcing us to jump through a whole new paradigm for a NDA approval process... given I think Restanza has national security implications, it is just unfathomable how it has become tied up in this situation. Would a JV be so complicated? Guess so...
ADLSD, you and I are through. Check out TLON folks, you can make it back over the upcoming months...
~~~~~~~~~~~~~~
"Politics is such a torment that I advise everyone I love not to mix with it." - Thomas Jefferson
My third post, and that is that... yep, it is quiet.
I am sure the longs are stunned. Simply, stunned.
Ouch. I know not what else to say, it is just awful on a daily basis. I see we do not talk in threads here, that is is like a room with a central dasis... a hall. Interesting...
I will not be taken down by this price action. I was contemplating two Bear lines the other day:
1) The market is smarter than you.
2) The market can stay illiquid and illogical far longer than you can remain liquid.
Well, Bears, which is it? Is the market always right, or is it very often wrong? Especially in a low volume environment?
We know it is the second. Which is why jokers like me can flip over 100% per year, with little effort.
I want these flash trading frontrunning mainframes at our money center banks turned off. Scalpers.
~~~~~~~~~~~~~
“What are politicians going to tell people when the Constitution is gone and we still have a drug problem?” - William Simpson
Welcome Hyrule...nice to see you on this board. There are certainly a lot less bashers and pumpers on here, but it has been quiet lately. Good for you averaging down to 33 cents...I myself need to hit over a dollar now to break even. It was much nicer to have to hit .04 to break even pre r/s. I'm not in a position to dedicate any more funds to this, being it is a gamble...and I am afraid to sell and rebuy for fear it will go up and I will miss out(happens to me all the time!)I too am long and wish you the best of luck, along with all the other longs out there.
For longs, simply average in very slowly.
That is my advice. And, no ADLSD board? That's cold.
Oh yeah, I was even on that pre-r/s bump to 1.14 cents,
now I sit 43% down, waiting for a nickle to add some more...
The sale never ends. I keep thinking to stop watching it,
but how do I know when to add or what to do if I tune out for
months? I dunno...
I wrote this just now:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=te&bn=95361&tid=16946&mid=16946&tof=1&frt=2#16946
I think I'll write here more often because I do not appreciate the censorship at Yahoo, I cannot even say this man's name:
Dick Van Dyke - Biography
http://www.imdb.com/name/nm0001813/bio
That's just wrong. And, there are too many Shorts there, only Shorts.
I am long ADLSD, current average at 33.9 cents. Buying, very slowly. This is a good overview, which many of you have surely seen...
http://www.dawsonjames.com/portal/ADLS_Initiation_11_23_10.pdf
~~~~~~~~~~~~~
"The prestige of government has undoubtedly been lowered considerably by the Prohibition law. For nothing is
more destructive of respect for the government and the law of the land than passing laws which cannot be
enforced. It is an open secret that the dangerous increase of crime in this country is closely connected with this."
- Albert Einstein
Looks like I'll be buying after YET ANOTHER RS soon!!!
This management needs to go!
100,000,000 shares!!! haha what a joke! Flavin keeps takin money out of people's pockets to pay his 6 figure salary!
this time you won't get approved Flavin!
http://phx.corporate-ir.net/phoenix.zhtml?c=190126&p=irol-SECText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDEwNDc0NjktMTEtMDAzMTc3L3htbA%3d%3d
30 split and will go back to same ticker 30 days yes...
Just checked my ROTH IRA and the ticker is now ADLSD. I assume it'll switch back after 30 days...
Bid is .20 ask is .30 and that's today's range. Over 11K traded and my 100,000 shares are now 3333 and I'd bought @ .0125 ( .30 is down 20%)
So I think it was a 1 for 30 split
I'll double down at some point but people need to find it to short it first. (LOL) Oh wait that sucks.
zilla,
Am i missing somthing here? i didn't see that price in last few weeks.
Hey JV, I've got 100K in my ROTH IRA at .0125 before the CC. I'll add more after the RS or ride what I've got. Sucks to see a drug like this and a POS PPS. (LOL)
CORSQ had some strength today with no massive panic.
What is the OS/As now with the RS underway?
No it is certainly not a pretty chart...but this drug IMHO works...It will either die or make some rich...keeping an eye it and looking at news will give us clues...after RS I will most likely get back in again...hopefully till FDA approval at around 10 dollars a share...JMHO...If this one dies it meant Corp/govt forces forced it to die!
JV44 I've been watching just about that long as well. The uncertainty of getting approved by the FDA and the chart keep me on the side lines.
You have to admit this is not a pretty chart over the past 2 years
Then on top of that you have articles that come out like this
which doesn't help matters.
By Petar Ilievski
Date: Mar 25, 2011
http://www.hotstocked.com/article/4314/the-bottom-of-advanced-life-sciences-holdings.html
Maybe one day that approval will come through
Still on the side lines watching
Ammobox
yah ...with a looming 30:1 R/S ...lol
.03 -.04 could be with in reach tomorrow
Absolutely...Waiting to jump in since July 09...LOL
JV, you might want to wait until after the reverse stock split before you buy. After the split, ADLS will drop more--somewhere around 50% or higher.
In my opinion..... Once they get the 38 mil grant the approval will come within 30 days. I hung on to Vanda for over 6 months while the FDA gave Lilly 4 months to come out with a similar drug. When Lilly's drug didn't work the FDA gave Vanda thier approval within 3 weeks, even though it was before the target date. I'm not saying they will use the money to bribe the FDA but.......
I've been waiying to jump back in...now I will wait a little longer....unless this drops to .000...then I dive...
Also the outlook/goals for 2011
"Business Outlook and Goals for 2011
•Support pending government funding submissions and submit additional proposals to develop Restanza as a biodefense and public health countermeasure;
•Advance discussions with prospective pharmaceutical company and government partners as part of our evaluation of strategic alternatives for the company;
•In-license additional value-enhancing pipeline candidates."
No mention of FDA approval.
Later guys.
Advanced Life Sciences Announces 2010 Fourth Quarter and Full Year Financial Results and Reverse Stock Split
prnewswire
Press Release Source: Advanced Life Sciences Holdings, Inc. On Thursday March 24, 2011, 8:00 am EDT
CHICAGO, March 24, 2011 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS.ob - News), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2010 and the approval of a 1-for-30 reverse stock split of the Company's issued and outstanding common stock.
(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)
Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences, commented: "During the fourth quarter, we continued to make progress toward our strategic objectives including the Restanza community acquired bacterial pneumonia (CABP) program and biodefense initiatives. Since the completion of our Agreement with the United States Food and Drug Administration (FDA) for the Special Protocol Assessment (SPA), we have discussed the Restanza opportunity with several potential strategic partners. Their views match that of ours in that there is an urgent need for new antibiotics that work through novel mechanisms of action, and that there is an alarming dearth of late-stage compounds that represent real partnering opportunities for companies that need to expand their antibiotic franchises. They also recognize that the regulatory landscape has shifted and companies developing antibiotics need to deal with the new set of guidelines. They believe that we have made significant progress in defining the new environment through our work with the FDA. We are hopeful that we will be able to convert this interest into a meaningful collaboration."
"As announced earlier this year, the Company has engaged in a strategic alternatives review process. While we continue to take steps to improve the financial standing of our Company, we believe that a potential strategic transaction, partnership or acquisition will be in the best interest of all our shareholders," said Dr. Flavin. "In the meantime, we will continue to advance our discussions and opportunities to work with the US Government regarding Restanza's potential in biodefense and global health."
The net loss allocable to common shareholders for the three months ended December 31, 2010 was $3.3 million or ($0.01) per share compared to a net loss allocable to common shareholders of $1.5 million or ($0.02) per share for the three months ended December 31, 2009. All share and per share information is presented on a pre-split basis. The increase in the net loss for the quarter is primarily due to a non-cash impairment charge which was partially offset by reduced salary and benefit costs and other operating expenses associated with the development of the Company's lead antibiotic, Restanza.
Cash used for operating activities during the quarter was approximately $1.0 million. In the fourth quarter, the Company raised approximately $0.8 million in proceeds through the use of a Standby Equity Distribution Agreement and made a $0.4 million commercial loan principal payment to further reduce outstanding debt. The Company ended the year with cash totaling approximately $0.2 million. Cash used for operating activities for the full year was approximately $6.4 million.
Full Year Expense Analysis, 2010 versus 2009:
* Research and development expenses decreased $2.0 million to approximately $2.5 million for the year ended December 31, 2010 from approximately $4.5 million for the year ended December 31, 2009. The decrease in R&D expense is due to lower government grant expenses associated with the Company's biodefense development program for Restanza as well as reduced salary and benefit costs and other operating expenses.
* Selling, general and administrative expenses decreased $1.9 million to $4.4 million for the year ended December 31, 2010 from $6.3 million for the year ended December 31, 2009. The decrease primarily reflects lower salary and benefit costs and other operating expenses.
Fourth Quarter Expense Analysis, 2010 versus 2009:
* Research and development expenses decreased by $1.1 million to approximately $0.2 million for the three months ended December 31, 2010 compared to $1.3 million for the three months ended December 31, 2009 due to lower government grant expenses associated with the Company's biodefense development program for Restanza.
* Selling, general and administrative expenses were reduced to $0.6 million for the three months ended December 31, 2010 from $0.9 million during the fourth quarter of last year due to reduced salary and benefit costs and other operating expenses.
2010 Achievements
* Achieved an agreement with the US Food & Drug Administration on the SPA for Restanza in CABP which provides a clear roadmap to approval;
* Responded to BARDA requests for information relating to a potential funding award to develop Restanza as a biodefense and public health countermeasure;
* Submitted a full contract proposal in response to a Broad Agency Announcement (BAA) issued by the National Institutes of Allergy and Infectious Diseases (NIAID) for the development of Restanza in IV formulation for the therapeutic treatment of multiple category A and B bacterial threats;
* Reported potent Restanza in vitro data in Burkholderia pseudomallei and Burkholderia mallei, which are important biodefense and global health related pathogens and announced positive data from an in vitro study assessing Restanza against 30 strains of Burkholderia pseudomallei, further highlighting its ability to address serious bacterial infections that are becoming untreatable due to the increasing public health threat of bacterial resistance to currently marketed antibiotics;
* Presented Restanza biodefense data and exhibited at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy;
* Announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza against the species of Plasmodium that cause malaria and entered into a Cooperative Research and Development Agreement (CRADA) with The Walter Reed Army Institute of Research to allow the institute to perform advanced animal efficacy testing of Restanza against various Plasmodium species that cause malaria;
* Expanded the collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STIs), such as gonorrhea;
* Announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of Restanza that support its use in a hospital setting;
* Reduced outstanding debt by $3.9 million in 2010 by completing a debt-for-equity exchange and a $1.9 million commercial loan principal payment;
* Awarded a $245,000 cash tax grant by the U.S. Internal Revenue Service through the Qualifying Therapeutic Discovery Project;
* Announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents.
Reverse Stock Split
The Company also announced today that a 1-for-30 reverse split of its common stock will take effect at 5:00 p.m. on Monday, March 28, 2011. The Company's common stock will be quoted on the OTC Bulletin Board on a split-adjusted basis beginning upon the opening of trading on March 29, 2011, under the symbol of ADLSD.OB. After 20 business days, the symbol will revert back to ADLS.OB.
As a result of the reverse stock split, every 30 shares of the Company's common stock issued and outstanding or reserved for issuance immediately prior to the effective time will be converted into one share of common stock. Fractional shares will not be issued and stockholders who otherwise would have been entitled to receive a fractional share as a result of the reverse stock split will receive an amount in cash the closing sales price of the Company's common stock as reported on the OTC Bulletin Board on March 28, 2011.
Letters of transmittal are expected to be sent to stockholders by the company's transfer agent, VStock Transfer LLC, shortly after the effectiveness of the reverse stock split. No action by the Company's stockholders is required prior to receipt of these letters.
The reverse stock split was approved by the Company's stockholders at the Company's annual meeting of stockholders held on April 8, 2010. The number of shares of common stock subject to outstanding stock warrants and options, and the exercise prices and conversion ratios of those securities, will automatically be proportionately adjusted for the 1-for-30 ratio provided for by the reverse stock split.
As part of the amendment to its certificate of incorporation to effect the reverse stock split, Advanced Life Sciences Holdings, Inc. will also reduce its authorized shares of capital stock from 625,000,000 to 25,666,666 shares and its authorized shares of common stock from 620,000,000 to 20,666,666 shares.
Business Outlook and Goals for 2011
* Support pending government funding submissions and submit additional proposals to develop Restanza as a biodefense and public health countermeasure;
* Advance discussions with prospective pharmaceutical company and government partners as part of our evaluation of strategic alternatives for the company;
* In-license additional value-enhancing pipeline candidates.
Financial Guidance for 2011
Advanced Life Sciences has taken certain cost cutting measures including a company-wide compensation reduction plan to further reduce its operating expenses. To fund ongoing operations in 2011, the Company intends to raise additional capital through the sale of equity while pursuing potential government contracts and commercial partnerships. The Company has approximately 25 million shares, on a pre-split basis, available for sale under the current equity facility with Dutchess Capital. There are approximately 184 million authorized shares, on a pre-split basis, remaining for subsequent equity financing opportunities. The Company is currently in default on its outstanding credit facility with Leaders Bank. Under the provisions of the loan agreement, Leaders Bank has certain rights and remedies including accelerating the loan repayment in which case the Company may have to file for bankruptcy protection. The Company is in discussions with Leaders Bank to resolve the current default.
Conference Call Details
Advanced Life Sciences will host a conference call and live webcast at 9:00 a.m. Eastern Time on Thursday, March 24, 2011 to discuss the Company's fourth quarter and year end financial results.
The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-713-4211 (domestic) or 617-213-4864 (international). The passcode for the conference call is 86880056. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PAVMV3UD3. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.
Reverse stock split..That explains
the tankage today.
A 1 for 30 split.. Jeez retards. Now I have to wait until .003 to buy or until after the reverse and the stock drops from 30 cents to around 10 cents.
What does that date mean? All it
says is "BARDA grant of $38 million."
Is there a summary post about ADLS on this board..Like a reasons to buy or DD thread? I can not find very much info on this one.
it all depends on what they are going to say tomorrow . smart money get in today better than play catching up . i hope u are right lol
This thing moves fast with very little $
The price can easily go back up to $.45 tomorrow
most of the trades today are buys . 1M buys VS 29K sells . some thing good coming ... at the end of the day we might see some more gain . tomorrow will be hard to catch it at this low price
Reminder - earning conference call tomorrow (i hope they say something good...)
http://biz.yahoo.com/cc/9/121309.html
The bigger the POS the stock is, the more appealing it is to me!
Super, I swear we probably look at about 80% of the same stocks. (LOL)
I remember trading this one in the .30-.40's range. I'd love for some excellent news to bring us up there. Without a RS of course. (LOL)
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2187
|
Created
|
04/20/07
|
Type
|
Free
|
Moderators |
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel drugs in the areas of infectious disease, oncology, and respiratory disease. Its lead candidate includes Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia. Cethromycin has also completed Phase III clinical trials for the treatment of respiratory tract infections. The company also has an exclusive worldwide license agreement with Abbott Laboratories for the development and commercialization of Cethromycin. Advanced Life Sciences? products under preclinical studies comprise ALS-357, a compound for the treatment of malignant melanoma; and ALS-886, a novel therapeutic for the treatment of inflammation-related tissue damage consisting of tissue damage associated with acute respiratory distress syndrome. Its products under preclinical studies also include product candidates derived from the company?s natural products-based chemistry platform. Advanced Life Sciences has collaborations and license agreements with Wyeth Pharmaceuticals, University of Illinois at Chicago, Baxter International, National Institute of Allergy and Infectious Diseases, and Defence Science and Technology Laboratory of the United Kingdom. The company was founded in 1999 and is headquartered in Woodridge, Illinois.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |